Neurocrine Biosciences Investor Relations Update

Neurocrine Biosciences has a dedicated investor relations team to keep shareholders informed about the company's progress.

The team is led by a seasoned professional with over a decade of experience in the biotech industry.

They provide regular updates through various channels, including the company's website, social media, and quarterly earnings reports.

These updates are designed to keep investors up-to-date on the company's pipeline, clinical trials, and financial performance.

The team also engages with investors through conference calls, webcasts, and one-on-one meetings.

This helps to foster a sense of community and transparency among investors, who can ask questions and get a better understanding of the company's strategy.

Neurocrine Biosciences has a strong track record of delivering on its financial and operational commitments.

For another approach, see: Team Investor Relations

Neurocrine Biosciences will present at various investor conferences in March. Their presentations will be webcast and available on their website.

Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the TD Cowen 44 Annual Healthcare Conference on Tuesday, March 5, 2024, in Boston.

The live presentations will be webcast and may be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com.

Here are the details of Neurocrine Biosciences' upcoming presentations:

A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.